14/12/2015 : Theradiag expands its biotherapy monitoring range, with a new CE marking obtained for its Entyvio® test

11th CE marking for the Lisa Tracker® rangeComplete range of monitoring tests for inflammatory bowel disease biotherapiesCroissy-Beaubourg and Montpellier, December 14, 2015 – THERADIAG (ISIN: FR0004197747, Ticker: ALTER), a company specialized in in vitro diagnostics…

Continue Reading 14/12/2015 : Theradiag expands its biotherapy monitoring range, with a new CE marking obtained for its Entyvio® test

08/12/2015 : RESULTS OF THE ROC TRIAL DEMONSTRATE THE BENEFITS OF MONITORING BIOTHERAPIES

Further validation of the value added by LISA TRACKER tests for monitoring treatments in rheumatoid arthritis patients with a loss of response Results presented at the American College of Rheumatology’s (ACR) Annual MeetingCroissy-Beaubourg, December 8,…

Continue Reading 08/12/2015 : RESULTS OF THE ROC TRIAL DEMONSTRATE THE BENEFITS OF MONITORING BIOTHERAPIES

18/11/2015 : THERADIAG AND HOB BIOTECH SIGN A STRATEGIC PARTNERSHIP IN ASIA AND IN EUROPE

HOB® Biotech will market Lisa Tracker® in China and in AsiaThis agreement is a cross-distribution and development agreement between two leaders in Auto-immunity, Allergy and biotherapy monitoringHOB® Biotech is  China’s market leader in allergy and…

Continue Reading 18/11/2015 : THERADIAG AND HOB BIOTECH SIGN A STRATEGIC PARTNERSHIP IN ASIA AND IN EUROPE